Literature DB >> 19949163

Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial.

Jeffrey J Sevigny1, Yahong Peng, Lian Liu, Christopher R Lines.   

Abstract

We explored the association of Alzheimer's disease (AD) Assessment Scale (ADAS-Cog) item scores with AD severity using cross-sectional and longitudinal data from the same study. Post hoc analyses were performed using placebo data from a 12-month trial of patients with mild-to-moderate AD (N =281 randomized, N =209 completed). Baseline distributions of ADAS-Cog item scores by Mini-Mental State Examination (MMSE) score and Clinical Dementia Rating (CDR) sum of boxes score (measures of dementia severity) were estimated using local and nonparametric regressions. Mixed-effect models were used to characterize ADAS-Cog item score changes over time by dementia severity (MMSE: mild =21-26, moderate =14-20; global CDR: mild =0.5-1, moderate =2). In the cross-sectional analysis of baseline ADAS-Cog item scores, orientation was the most sensitive item to differentiate patients across levels of cognitive impairment. Several items showed a ceiling effect, particularly in milder AD. In the longitudinal analysis of change scores over 12 months, orientation was the only item with noticeable decline (8%-10%) in mild AD. Most items showed modest declines (5%-20%) in moderate AD.

Entities:  

Mesh:

Year:  2010        PMID: 19949163     DOI: 10.1177/1533317509350298

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  8 in total

1.  Visuo-constructional functions in patients with mild cognitive impairment, Alzheimer's disease, and Parkinson's disease.

Authors:  Johann Lehrner; Harald Krakhofer; Claus Lamm; Stefan Macher; Doris Moser; Stefanie Klug; Peter Dal-Bianco; Walter Pirker; Eduard Auff; Gisela Pusswald
Journal:  Neuropsychiatr       Date:  2015-04-11

2.  The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.

Authors:  Nandini Raghavan; Mahesh N Samtani; Michael Farnum; Eric Yang; Gerald Novak; Michael Grundman; Vaibhav Narayan; Allitia DiBernardo
Journal:  Alzheimers Dement       Date:  2012-11-02       Impact factor: 21.566

3.  Relationship between areas of cognitive functioning on the Mini-Mental State Examination and crash risk.

Authors:  Carrie Huisingh; Virginia G Wadley; Gerald McGwin; Cynthia Owsley
Journal:  Geriatrics (Basel)       Date:  2018-03-06

4.  Basal Forebrain Volume, but Not Hippocampal Volume, Is a Predictor of Global Cognitive Decline in Patients With Alzheimer's Disease Treated With Cholinesterase Inhibitors.

Authors:  Stefan J Teipel; Enrica Cavedo; Harald Hampel; Michel J Grothe
Journal:  Front Neurol       Date:  2018-08-14       Impact factor: 4.003

5.  Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease.

Authors:  John E Harrison
Journal:  Alzheimers Res Ther       Date:  2018-06-29       Impact factor: 6.982

6.  Determining Filipino Normative Data for a Battery of Neuropsychological Tests: The Filipino Norming Project (FNP).

Authors:  Jacqueline Cotoong Dominguez; Thien Kieu Thi Phung; Ma Fe Payno de Guzman; Krizelle Cleo Fowler; Macario Reandelar; Boots Natividad; Gunhild Waldemar; Thomas Rune Nielsen; Mary Rose Pamintuan Aquial; Rachelle Layda Holandez; Antonio Disederio Ligsay
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2019-08-13

7.  Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer's Disease.

Authors:  Charles F Murchison; Byron C Jaeger; Jeff M Szychowski; Gary R Cutter; Erik D Roberson; Richard E Kennedy
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

8.  Describing the Sequence of Cognitive Decline in Alzheimer's Disease Patients: Results from an Observational Study.

Authors:  Carsten Henneges; Catherine Reed; Yun-Fei Chen; Grazia Dell'Agnello; Jeremie Lebrec
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.